Fig. 2From: A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrenceKaplan–Meier estimate of the progression-free survival for participants assigned to receive observation (blue) or CC-486 (green). Individuals were considered to have progressed if they had progression confirmed by radiography or biopsy or diedBack to article page